Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
about
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemiaThe emerging role of ofatumumab in the treatment of chronic lymphocytic leukemiaBCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic LeukemiaImmunotherapy in Chronic Lymphocytic Leukaemia (CLL)Current concepts in diagnosis and treatment of chronic lymphocytic leukemiaLenalidomide and chronic lymphocytic leukemiaChronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatmentTherapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemiaMeta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature.Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II studyThe combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin's lymphoma (B-NHL) chemotherapy: a meta-analysis.Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyA phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey.Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials.Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroupsCyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drugU.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cellsCancer immunotherapy in clinical practice -- the past, present, and future.Anti-CD37 antibodies for chronic lymphocytic leukemia.A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapCurrent and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.The spectrum of use of rituximab in chronic lymphocytic leukemiaMonoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia.Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumabClinical relevance and treatment of nonautoimmune anemia in chronic lymphocytic leukemia.Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.
P2860
Q24203027-1D8AF175-7918-4690-9E7E-648D9DB2BE80Q24617708-DE9A629A-0044-43F0-858F-08D1A5D2ACD0Q26765624-231C75E5-9261-4BF3-8887-6002BC624378Q26768154-ECD1E4BE-9302-49EF-90B7-4BFAFF981BCDQ26770471-D01987CC-BDA5-4D21-92B0-3C9E73175F63Q26823597-314A201F-A2FD-4A8F-ADB0-120FD157BF25Q28082086-2DA77BC6-65FD-464C-A1AB-E9570DE3C1E3Q28087378-6D56D2D5-D199-4F01-A094-7718CF423A17Q30249335-7900B5CB-D2B7-4182-8C4B-B9EB95EE7842Q31033615-CD802CE7-535F-4E5F-953C-A1D5DA12C3ACQ33391919-94CC329B-978B-4C9F-B76F-D7A68837E50FQ33394308-DBB7D521-3AFF-465A-9B7A-6D2DD30AB3BBQ33396594-13388FA9-78BB-4B6C-9557-8F6644D4C2F9Q33404763-0B12D20C-6B90-4C8C-900C-AC477F96E6FFQ33406164-D4CCF8FB-511D-4811-A22F-8C3AE6FFE42EQ33416569-528DA553-F55E-4457-9952-F5963C1D1381Q33421964-DC63C882-27B3-4AE2-8378-A8231E62695EQ33429161-1EE008AE-7D3D-448E-8598-F178E9891AACQ33438428-2F67DFA1-5455-4BC8-A452-A269DEEAB2B1Q33591830-4859EAA1-DDF5-441B-BD14-0E3F25C80A43Q33668990-F63130CA-106A-4361-9561-8701A48F866EQ33673144-C6B4250A-0D18-4D1E-A920-C511AD7C64F5Q33695990-26E5512A-8F46-419F-9DE6-B744D811E299Q33913537-35978F15-FED8-402C-A532-C8773F32ACB2Q34008593-78E87C21-A287-4E08-BA78-8E5141C19E7FQ34008866-59FD7576-D771-4DD9-A7B8-5FCDC3418DDBQ34065271-710F51BE-F2C5-4F65-B7CC-89AFB8F5587EQ34157931-5B3E2DE8-EA20-42AD-898D-A8B88CEBF22DQ34193553-B23461AF-B8D9-4719-9403-FF20E855450CQ34309399-23C75857-7694-4BD3-9074-75641DE55866Q34405641-8BA8E158-FDD3-4491-9214-BCE372F3F56FQ34433926-CDA4DE38-9FA4-4F42-8D15-B67569352F06Q34440110-552CA014-DB3C-4EF0-8A3E-B823036B3EBEQ34510030-D0F7D6B2-9161-4C5E-8246-E7233A94E0BBQ34700655-B1A251AC-A1B8-495B-937D-DA3666DDB341Q34769213-55126D8C-C051-44D2-85BC-3D3EBDA5BBCAQ34974058-3F8DEDCA-72DD-4BE3-A5C2-C819945E0E38Q35076449-C5A96934-1279-4E91-87B3-01C20721412BQ35114910-A1CE8D45-AB9D-4B73-A667-291981285777Q35123154-23CB6422-5223-45AA-ADF0-72D50CA63F7C
P2860
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Rituximab plus fludarabine and ...... chronic lymphocytic leukemia.
@en
Rituximab plus fludarabine and ...... chronic lymphocytic leukemia.
@nl
type
label
Rituximab plus fludarabine and ...... chronic lymphocytic leukemia.
@en
Rituximab plus fludarabine and ...... chronic lymphocytic leukemia.
@nl
prefLabel
Rituximab plus fludarabine and ...... chronic lymphocytic leukemia.
@en
Rituximab plus fludarabine and ...... chronic lymphocytic leukemia.
@nl
P2093
P50
P356
P1476
Rituximab plus fludarabine and ...... d chronic lymphocytic leukemia
@en
P2093
András Rosta
Boris V Afanasiev
Caroline Dartigeas
Christian H Geisler
Ilya Zyuzgin
Javier Loscertales
John Catalano
Jörg Maurer
Loree Larratt
M Wayne Saville
P304
P356
10.1200/JCO.2009.26.4556
P407
P577
2010-03-01T00:00:00Z